Nivolumab-induced sensory ganglionopathy.

Ozlem CoskunHasan SahinSelim YalcinYekta C SahinUgur Coskun

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Sensory ganlionopathy can be seen as a side effect of an immune checkpoint inhibitor, even though it is very extraordinary. This is the case in the literature to develop sensory ganlionopathy due to nivolumab. We believe that patients using nivolumab may develop sensory ganlionopathy and management should be taken on this point.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
systematic review
chronic kidney disease
peritoneal dialysis
high glucose
prognostic factors
endothelial cells
patient reported outcomes
diabetic rats